Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

NEW YORK, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient randomization in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial of AXS-05 in patients with treatment resistant depression (TRD). AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. Axsome remains on track to report topline results from STRIDE-1 in the first quarter of 2020.

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

Axsome Had A Monumental Run, But Its Long-Term Potential Has Only Begun

Seagen

Vertex Pharmaceuticals

Shares of these biotech companies are near their five-year highs after some strong performances in 2019.

Are Biotech Stocks Due for a Correction in 2020?

Incyte

Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.

2 Top Growth Stocks to Buy in January

Galapagos

Lexicon Pharmaceuticals

These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q1 2020.

Top Biotech Stocks for Q1 2020

Cannae Hlds

Southwestern Energy

These are the small cap stocks with the best value, fastest growth, and most momentum for January.

Top Small Cap Stocks for January 2020

The stock had an amazing run in 2019, with a 3,578% gain. What will happen in 2020?

Axsome Therapeutics: Buy at the High?

ArQule

Constellation Pharmaceuticals Inc

DURECT

EverBank Financial

IVERIC bio Inc

Kodiak Sciences Inc

Provention Bio Inc

AVITA Medical Inc

Stage Stores

These Were the 10 Best Stocks of 2019

Guardant Health Inc

Intuitive Surgical

Three very different areas of healthcare. One big common denominator: great growth prospects.

3 Top Healthcare Stocks to Buy in January

Fate Therapeutics

Pfizer

Some of the biggest catalysts for future growth in drug stocks include the millions of retiring baby boomers, and new innovative treatments for a variety of medical issues.

3 Top Drug Stocks to Own In 2020

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

Find out what's behind the biopharmaceutical industry's top-performing stock of the year.

4 Reasons Axsome Therapeutics Soared 3,600% in 2019

Axsome Therapeutics Inc (NASDAQ: AXSM) shares, which had a rip-roaring 2019, are poised to add to the gains Monday.

Axsome Shares Target New Highs After Migraine Drug Aces Late-Stage Trial

These stocks have soared 935% or more this year. Can they keep the momentum going?

3 Best Biotech Stocks of 2019: Are They Buys Now?

Here's why these drugmaker stocks are the year's top performers.

3 Biotech Stocks That Crushed It in 2019

Axsome Therapeutics: A Company With Booming Catalysts And A Remarkable Innovation In Treating Depression

ACADIA Pharma

Acadia Pharmaceuticals and Axsome Therapeutics are top buyout candidates heading into the new year.

2 Biotech Stocks Poised to Soar in 2020

NEW YORK, Dec.  23, 2019  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 2,300,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at the public offering price of $87.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and other estimated offering expenses, were $200.1 million.

Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Karuna Therapeutics Inc

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Can These Soaring Biotech Stocks Fly Higher?

Bed Bath & Beyond

ImmunoGen

Comscore Inc.

These four stocks are moving on news and gaining technical momentum: Axsome Therapeutics, Inc.

4 Momentum Stocks To Watch: AXSM, BBBY, IMGN & SCOR

Favorable clinical results? Check. Cash from public stock offering?

Here's Why Axsome Therapeutics Shares Jumped Again Today

NEW YORK, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $87.00 per share. The proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Axsome, are expected to be $174.0 million. In addition, Axsome has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 23, 2019, subject to customary closing conditions.

Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

Is the company's new clinical drug the blockbuster many are hoping it to be?

How Big of a Deal Is Axsome Therapeutics' New Depression Drug?

NEW YORK, Dec.  17, 2019  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:^NBI), as part of the annual index evaluation. The Company’s addition to the index will become effective prior to the market open on Monday, December 23, 2019.

Axsome Therapeutics Added to NASDAQ Biotechnology Index

Axsome Therapeutics (AXSM) news for Monday about results from the company's Phase 3 Trial of AXS-05 has AXSM stock rocketing higher.
The post Axsome Therapeutics News: AXSM Stock Rockets 76% on Depressive Disorder Drug Results appeared first on InvestorPlace.

News for Axsome Therapeutics Stock (AXSM)